GATA3 inhibits primary breast tumor outgrowth and reduces lung metastatic burden by regulating key genes involved in metastatic breast tumor progression.

The expression of GATA3 and TTF1 distinguishes metastatic mammary carcinoma from primary lung carcinoma.

In resected lung adenocarcinoma, high GATA3 expression is associated with poorer prognosis for both overall survival and disease free survival.

GATA-3 expression was the highest in luminal breast carcinomas, and showed higher sensitivity than GCDFP-15 and MGB. However, in the poorly differentiated IBC, its utility was still limited. One should be aware of the possible GATA-3 expression in lung carcinomas.

GATA3 interacts with and is acetylated by the acetyltransferase CBP. The major acetylated site of GATA3 in lung adenocarcinoma cells is lysine 119.

Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From pulmonary Sarcomatoid Carcinoma.

Data suggest a pro-metastatic GATA3 Transcription Factor (GATA3)- lysyl hydroxylases (LHs) axis for lung cancer, supporting the notion that targeting LHs may be useful for treating lung cancer.